AVI BioPharma names chief executive

Chris Garabedian joins US biopharmaceutical firm from Celgene

Chris Garabedian will become chief executive and president of AVI BioPharma on 1 January 2011.

Garabedian, who has been a director of the Bothell, Washington-based biopharmaceutical firm since June, will continue as a member of the board. David Boyle, who held the post of interim ceo and president, will continue in his role as chief financial officer and senior vice president.

Garabedian brings to AVI broad biotechnology and pharmaceutical experience. He has been vice president of corporate strategy at Celgene since July 2007. Before this, he held several key roles at Gilead Sciences between 1997 and 2005, including vice president of corporate development, vice president of marketing and vice president of medical affairs.

He also held various commercial and product development roles at COR Therapeutics and Abbott Laboratories and began his career as a consultant to the pharmaceutical industry.

‘We believe Chris' experience is ideal for driving products from early development through commercialisation, while also leveraging business development opportunities to unlock further value from our RNA-based therapeutics technology platforms,’ said William Goolsbee, AVI's chairman.

You may also like

Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Research & Development

SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials

Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Research & Development

SeaBeLife awarded over €1.5 million in i-Nov innovation competition

Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Subscribe now